Abstract
Etanercept is an antagonist of tumor necrosis factor alpha that was developed to treat rheumatoid arthritis. In this report we present a patient who developed myasthenia gravis while taking etanercept and had resolution of symptoms after stopping it. This is the first report of this potential side effect and is of additional interest, because etanercept has been proposed as a treatment for myasthenia gravis.
MeSH terms
-
Aged
-
Antirheumatic Agents / administration & dosage
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Arthritis, Rheumatoid / physiopathology
-
Autoantibodies / blood
-
Autoantibodies / drug effects
-
Deglutition Disorders / chemically induced
-
Deglutition Disorders / immunology
-
Deglutition Disorders / physiopathology
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects*
-
Male
-
Muscle, Skeletal / drug effects
-
Muscle, Skeletal / physiopathology
-
Myasthenia Gravis / chemically induced*
-
Myasthenia Gravis / immunology
-
Myasthenia Gravis / physiopathology
-
Neuromuscular Junction / drug effects
-
Neuromuscular Junction / immunology
-
Neuromuscular Junction / metabolism
-
Pharynx / drug effects
-
Pharynx / physiopathology
-
Receptor Protein-Tyrosine Kinases / drug effects
-
Receptor Protein-Tyrosine Kinases / metabolism
-
Receptors, Cholinergic / drug effects
-
Receptors, Cholinergic / immunology
-
Receptors, Cholinergic / metabolism
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Antirheumatic Agents
-
Autoantibodies
-
Immunoglobulin G
-
Receptors, Cholinergic
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
MUSK protein, human
-
Receptor Protein-Tyrosine Kinases
-
Etanercept